RxDoctor Payments Data

Uma Thanarajasingam, MD

Rheumatology · Rochester, MNNPI 1790949378

Payments from drug & device makers

What this record shows

That places this record below the midpoint for rheumatology clinicians in MN, where the typical reported total is $70.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$399,017in research payments, 2019–2025

Across 16 payments — averaging $24,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$231K
  • E.r. Squibb & Sons, L.L.C.$148K
  • UCB SA$21K

How this compares

$0 in reported general payments places this provider in the 30th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$34,089
Medicare patients
124
Services billed
1,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast13$63,771
Hydroxychloroquine Sulfate76$3,085
MethotrexateMethotrexate Sodium30$1,409
Prednisone130$1,312
Mycophenolate Mofetil13$1,279
Pilocarpine Hcl11$1,048

Paid to pharmacies, not to this prescriber.

Other rheumatology in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →